AC Immune's Partner Janssen Temporarily Pauses Enrollment in Phase 2b Alzheimer's Trial

summarizeSummary

AC Immune announced that its partner Janssen has temporarily paused enrollment in the Phase 2b ReTain study for ACI-35.030/JNJ-2056 in preclinical Alzheimer's disease, citing evaluation of trial aspects including recruitment.

check_boxKey Events

• Janssen Pauses Enrollment in Alzheimer's Trial

  Janssen Pharmaceuticals, AC Immune's partner, has temporarily paused recruitment for the Phase 2b ReTain study of ACI-35.030/JNJ-2056 in preclinical Alzheimer's disease.

• Pause Not Safety-Related, Immunogenicity Threshold Met

  The company stated the pause is voluntary, not due to new safety findings, and the trial's pre-specified interim immunogenicity threshold was met.

• No Immediate Liquidity Impact

  AC Immune reiterated that the pause does not affect its current liquidity, with existing capital sufficient into Q3 2027, excluding potential milestone payments.

• Other Pipeline Updates Provided

  The company anticipates reporting clinical results for other active immunotherapy programs in 2026, including ACI-24.060 (Alzheimer's) and ACI-7104.056 (Parkinson's), and expects a Phase 1 trial for ACI-19764 (NLRP3 inhibitor) to start dosing soon.

auto_awesomeAnalysis

AC Immune announced that its partner Janssen has temporarily paused enrollment in the Phase 2b ReTain study for ACI-35.030/JNJ-2056, a key Alzheimer's disease candidate. While the company emphasized the pause is voluntary, not safety-related, and the interim immunogenicity threshold was met, any delay in a pivotal clinical trial, especially for a major partnered program, introduces uncertainty and pushes back potential milestone payments and market entry. This could weigh on investor sentiment despite the company's reiteration of its liquidity position into Q3 2027 and updates on other pipeline programs.